Syndax Pharmaceuticals Inc (SNDX): Entry into a Material Definitive Agreement
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 d105044dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version SYNDAX PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 10, 2026 2.25% Convertible Senior Notes due 2031 TABLE OF CONTENTS P AGE ARTICLE 1 DEFINITIO
How this was made
The 30-second read
Why it matters
New convertible debt can shift the company’s capital structure and introduce equity-linked dilution/hedging dynamics; traders may reprice risk premia until full terms (pricing, size, conversion mechanics) are known.
Market read
Convertible debt issuance is a concrete financing catalyst that can affect equity valuation through dilution expectations and balance-sheet risk.
What to watch
Key missing details (aggregate principal amount actually issued, conversion premium, call/repurchase provisions, and use of proceeds) can materially change dilution and credit-risk interpretation.
Background
The filing is an SEC Form 8-K describing entry into a material definitive agreement and the creation of direct financial obligations via an indenture for 2.25% convertible senior notes due 2031.
Ticker impact
Syndax entered a material definitive agreement for 2.25% convertible senior notes due 2031, creating new direct financial obligations.
Likely modest volatility around capital-structure/dilution expectations; direction depends on issue size/terms not shown in the excerpt.
This is a primary SEC filing (8-K) tied to issuance terms (2.25% converts due 2031) but the excerpt does not provide pricing, size, or proceeds, limiting precision on equity impact.
Market effects
Financing via convertibles is common in biotech; could modestly influence read-across for funding conditions and dilution risk appetite.
Primarily US capital markets; limited direct regional spillover beyond US biotech credit/equity sentiment.
Low—convertible issuance is mostly local to US investors unless cross-listed or syndicated internationally (not indicated here).
Counterpoint
If the convertible is structured favorably (e.g., limited dilution, strong investor demand), the equity overhang may be smaller than typical convertibles imply.
Key entities
- issuerSyndax Pharmaceuticals, Inc.
Company entering the convertible notes indenture agreement disclosed in the 8-K.
- trusteeU.S. Bank Trust Company, National Association
Trustee named in the indenture for the convertible senior notes.
